The FT Global Pharmaceutical and Biotechnology Conference, now in its 35th successful year brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in this new era of unprecedented disruption and uncertainty.
FT Global Pharmaceutical and Biotechnology Conference
Thriving Amid Uncertainty
The Merck Group
With the Support Of
Days until event:
“This FT conference has become an annual leadership forum on the international stage, it’s a really important event for London and the UK.”
The Rt Hon George Freeman, Minister for Life Sciences UK
“The FT is always at the centre of what goes on in the industry. It’s a great source for all kinds of information and this conference for me is a great way to keep up with the trends and figure out what’s going on in the industry.”
Dr Flemming Ornskov, Chief Executive Officer, Shire
“Great conference to get an update on the strategic direction of global pharma from senior decision makers.”
Emily Lekkas, Scottish Development International
“A very relevant event for pharma/biotech, investors and industry observers.”
Guy Martin, The Pharma Letter
“The conference offers a tremendous opportunity to learn perspectives and insights on business models and medical value.”
Tim Durham, Takeda Pharmaceuticals
As old world certainties regarding payments, products and patients are swept away in a tidal wave of pricing pressures, growing geopolitical uncertainties and the new world realities of value, data and outcomes, life science companies will need to find new ‘ways to play’ if they are to adapt and compete in the new health economy which is emerging. Opportunities in the prevention, treatment and care of patients across key therapeutic areas including Alzheimer’s, cancer and other diseases of ageing, as well as the burgeoning field of precision medicine present opportunities, but can life science companies successfully play to their strengths in IP, regulation and high science to navigate the new terrain and ensure their place at the table?
Kemal Malik was appointed to the Board of Management of Bayer AG in 2014. He is responsible for Innovation across the Bayer group (pharmaceutical, crop science and consumer health). He has over twenty years of experience in the global pharmaceutical industry. He joined Bayer in 1995 and held positions of increasing responsibility in the Global R&D organisation. He was appointed Head of Global Development in 2003 within Bayer Healthcare, also becoming a member of the Executive Committee. In this role he was responsible for the advancement of Bayer’s pipeline across all therapeutic areas.
He initially joined Bristol-Myers Squibb, holding various positions in medical affairs and clinical development. Dr Malik studied medicine in London and subsequently spent several years at the Northwick Park Clinical Research Centre and at the Hammersmith Hospital, London.
David Meek was appointed Ipsen’s CEO in 2016, and also serves on the company’s Board of Directors. He joined from Baxalta Inc, where he was Executive Vice-President and President of the Oncology division. Prior to this, he spent 14 years in the US at Johnson & Johnson and Janssen Pharmaceutica, in senior commercial roles across multiple therapeutic areas in specialty and primary care. He also served as Chief Commercial Officer of Endocyte, an oncology biotechnology company in the US. Earlier in his career, Mr Meek was at Novartis for nine years, successively serving as a Global Business Franchise Head in Basel, Switzerland; President and CEO of Novartis Canada; and the Head of Oncology for Northern, Central and Eastern Europe based in Italy. Prior to his biopharma career, Mr Meek was an officer in the United States Army. He is a graduate of the University of Cincinnati.
Belén Garijo is a Member of the Executive Board of Merck, a position she has held since January 2015. In this role, she is responsible for the Healthcare business sector, comprising the Biopharma, Consumer Health, Allergopharma and Biosimilars businesses. Since 2013 she also acts as President and CEO of the Biopharma business, where she started in 2011 as Chief Operating Officer. Before joining Merck, Dr Garijo was employed by Sanofi-Aventis as Senior Vice President Global Operations Europe, serving as a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the
Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003 she served as Global Vice President Oncology at Aventis and from 1996 as Director of the
Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer. Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA. Dr Garijo is a medical doctor, specialised in clinical pharmacology. She worked as a practicing physician for six years, before moving to the pharmaceutical industry.
Lisa Urquhart is editor of EP Vantage, a leading online news and analysis service covering the pharma, biotech and medtech industries. A journalist with more than a decade of industry experience, Lisa joined EP Vantage from the Financial Times, where she held a variety of positions, including biotechnology correspondent. Lisa is an active contributor to industry panels and articles and has commented on the pharmaceutical industry on both television and radio, focusing on business models, M&A and R&D strategies and innovation. In 2011 she was part of the EP Vantage team that won European Mediscience Commentator of the Year.
Steve Cutler was appointed Chief Executive Officer of ICON in March 2017, having previously served as Chief Operating Officer. He is also a member of ICON’s Board of Directors. Dr Cutler joined ICON in 2011 and served as Group President, Clinical Research Services until his appointment as Chief Operating Officer in 2014. Dr Cutler has over 28 years of pharmaceutical industry and CRO experience. Prior to ICON, he was Chief Executive officer of Kendle and oversaw the sale of the company to INC Research. Prior to Kendle, Dr Cutler held various operational and general management roles in both Quintiles and Sandoz (Novartis).
Knut Slatten is a Senior Analyst at Moody’s, working in the Moody’s EMEA Corporate Finance Group. He is currently lead analyst for European pharmaceuticals and has covered European healthcare names for Moody’s since 2007. Prior to joining Moody’s, Mr Slatten worked as a credit analyst for Société Générale in Paris. Mr Slatten holds an MSc in Economics from the Norwegian School of Economics and Business Administration (NHH) and completed I a CEMS Master’s degree n Groupe HEC in Paris, France.
Tauhid Ali is Vice President, Head TAK-celerator, Center for External Innovation at Takeda Pharmaceuticals International. Tauhid Ali serves as Vice President, Head Takeda TAK-celerator, a group focused on accelerating transformative therapies for people with rare diseases or indications where there remains a significant unmet need. The TAK-celerator is part of Takeda’s Center for External Innovation (CEI) organisation, adopting an incubator-like model to develop and externalise effective therapies. Its mission is to move assets through translation into novel therapies whereby externalisation paths, such as creation of new companies or collaborations with external partners, are made possible to increase the chances of reaching more patients. The TAK-celerator operates a very lean and entrepreneurial model primarily utilising external services and leveraging an extensive knowledge-based network. With more than 20 years international experience in the biopharmaceutical industry, Dr Ali has broad management and leadership experience in translational research, corporate strategy, global development and global project leadership. His work encompasses development of both small molecules and antibody therapeutics within a broad range of therapeutic areas, including oncology, autoimmune/inflammatory diseases, as well as orphan diseases. Dr Ali gained his PhD.from Cardiff University and a MSc in Clinical Sciences from the Welsh School of Pharmacy.
Fleming Ornskov assumed the position of Chief Executive Officer in April, 2013 and has been a member of the Board since January, 2013. Dr Ornskov brings to his position his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG, and of Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer. Prior to this, from 2008 to 2010, Dr Ornskov served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Dr Ornskov had roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. He received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.
Christian brings a valuable mixture of clinical and business expertise to Mundipharma, having trained as a physician before joining management consultancy Bain & Company where he progressed to partner and head of the UK healthcare practice. He worked in the firm’s Boston, Zurich and London offices, leading assignments in strategy, M&A, technology/pipeline valuation, product launch, sales force effectiveness, turnaround and restructuring.
Christian heads Mundipharma’s European therapy area franchises, including pain, respiratory, biosimilars, oncology and addiction therapy. He is also responsible for the established brands business unit and market access in Europe.
He holds degrees and training from INSEAD (MBA), the University of Sydney, Australia (Med) and Boston University, US (BS and BSBA) and is fluent in five languages.
Karenann joined GSK as Chief Digital & Technology Officer in September 2017 with a company-wide remit to transform how new technologies are used to improve performance across the Group. She is a member of the Corporate Executive Team.
She is responsible for GSK’s digital, data and analytics strategy. She works with a wide range of partners from inside and outside the healthcare sector to bring new technologies to GSK, enhancing areas such as clinical trials and drug development; improving how we interact with healthcare professionals, customers and consumers; and making internal processes more efficient.
Karenann’s previous role was Chief Information Officer for Walmart, where she led a multi-year effort to transform Walmart in the use of data, analytics and digital engagement with its customers. Prior to Walmart she was at Baxter International, where she was Chief Information Officer, and before that Daimler Chrysler Corporation. Karenann began her career in General Motors and held various roles in manufacturing, engineering and brand management.
Karenann is a member of the board of trustees for the New York Hall of Science, a hands-on science and technology centre.
She earned graduate and post-graduate degrees in Electrical Engineering from Kettering University and Purdue University, respectively.
Vivek Ramaswamy is Founder and Chief Executive Officer of the Roivant Sciences family of companies. The Roivant Sciences family includes five wholly-owned or majority-owned subsidiaries, each focused on a different disease area: Axovant (neurology), Myovant (women’s health and endocrine diseases), Enzyvant (rare diseases), Dermavant (dermatology), and Urovant (urology). The group has 14 drugs in its pipeline and has raised over $2.5bn in capital to date to fund late-stage clinical programs and pursue adjacent business opportunities. Prior to founding Roivant, Mr Ramaswamy was an investor in the biotechnology sector. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences, Myovant Sciences, and Roivant Sciences. He received an A.B. summa cum laude in Biology from Harvard College and a J.D. from Yale Law School.
Michael West, Ph.D
Michael West is the founding CEO of AgeX Therapeutics, a biotechnology company focused on the emerging field of interventional gerontology. AgeX is a subsidiary of BioTime, Inc, where Dr West also serves as Co-CEO, having joined as CEO in 2007. Prior to that he served as President, CEO and Chief Scientific Officer of Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in 2016. In 1990, Dr West founded Geron (Geronology) Corp., which may have been the first regenerative medicine company, with backing from Kleiner, Perkins, Caufield Byers and Venrock, and recruited for its scientific team Drs. Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the Nobel Prize in Medicine. While at Geron, he also created the research consortium that led to the first isolation of human embryonic stem cells. Dr West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. in Biology from Andrews University in 1982, and a PhD from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He is the author of The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging (DoubleDay, 2003).
Mr Hogg joined Chi-Med in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the company’s strategy, business and listings. This includes the establishment of the company’s Innovation Platform, which now comprises eight clinical drug candidates, primarily in oncology, in over 30 clinical studies around the world and a scientific team of over 330 people based in Shanghai. Furthermore, the acquisition and operational integration of assets that led to the formation of the company’s Commercial Platform which manufactures and markets over 200 drugs through a team of over 3,300 marketing personnel covering over 300 cities and towns in China. Prior to joining Chi-Med, Mr Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.
Kobi Gershoni is Co-founder and Chief Research Officer of Signals Analytics. Prior to co-founding Signals Analytics, Mr Gershoni was a Senior Analyst and Information Officer for an elite intelligence unit in the Israel Defense Forces, where he began to contemplate and refine the incorporation of open source intelligence into the growth plans of consumer brands and innovation agendas of life sciences companies. Mr Gershoni holds an MBA in Finance and Strategy as well as a BA in International Relations from Hebrew University in Jerusalem.
In 2010, Rolf Smeets was appointed Chief Medical Officer of Nutricia Advanced Medical Nutrition ,the medical nutrition business of Danone. Dr Smeets started his career in Research & Development in 1998 at Nutricia, leading nutritional research for disease management in oncology, cardiology and renal failure. In 2000, he led a research project in Sports Nutrition, and in 2002 was named Director of New Product Development for nutritional supplements company GNC in the USA. In 2003, Dr Smeets returned to The Netherlands as Director Medical Nutrition Research. Following the acquisition of Nutricia by Danone, Dr Smeets assumed responsibility for Research & Development for Danone’s Activia dairy brand. Dr Smeets obtained his PhD in Medical Sciences in 1998 from Radboud University in Nijmegen and holds an European Executive MBA from the University of Groningen.
Beijia Ma is a Strategist on the Thematic Investing team at Bank of America Merrill Lynch in London. The team addresses long-term thematic issues both from an opportunity and risk perspective - including climate change, cybersecurity, education, energy efficiency, food security, longevity, millennials, obesity and health & wellness, pandemics, robots & AI, safety & security, waste, and water. The team publishes primers, quarterly Global Megatrend Primer Picks, and monthly Theme Watch reports. Prior to joining the Thematic Investing team, Ms Ma was an Equity Derivatives Trader at Bank of America Merrill Lynch in New York. She holds a BS with Honors in Biology from Stanford University.
Ameet Nathwani was appointed as Executive Vice President, Group Chief Medical Officer and Global Head of Medical Function of Sanofi in May, 2016. Dr Nathwani is responsible for enterprise-wide medical, patient safety, medical quality assurance and ensuring the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organizations. A UK. citizen, born in Uganda and educated in the UK, Dr Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over a period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability. Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Office, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval and commercialisation, which included $11bn in global sales, the largest oncology pipeline in the industry, and a workforce of 8,000 employees in 50 countries. Mr Hoppenot joined Novartis in 2003 and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr Hoppenot holds a Diploma from ESSEC Business School.
Sarah Emond leads the strategic planning and operations of the Institute for Clinical and Economic Review(ICER), a leading non-profit health policy research organisation, as Executive Vice President and Chief Operating Officer. In that role, she is responsible for overseeing ICER’s public programs, communications, operations, and finances.
Prior to joining ICER, Ms Emond spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. She began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy. She also received a Bachelor’s degree in Biological Sciences from Smith College.
Othman Laraki is co-founder and CEO of Color. He spent several years at Google, where he worked on Google’s performance infrastructure and client-side software, including the Google Chrome browser. Following Google, he co-founded MixerLabs, which was acquired by Twitter in 2009. At Twitter, Othman was the Vice President of Product, helping create the company's first revenue products and grow the user base from 50 to 200 million users. Othman holds degrees in computer science and management from Stanford University and the Massachusetts Institute of Technology. Othman is a long-time investor and advisor to leading companies such as Pinterest, AngelList, Slack, Instacart and others.
Bahija Jallal is Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She is a member of the senior executive team at AstraZeneca reporting to the CEO. She joined MedImmune in March 2006. In addition to her roles at AstraZeneca, Dr Jallal is a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organisation that manages biomedical research development at the University’s BioPark. She was recently appointed to the Board of Trustees of The Johns Hopkins University. Dr Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory board member of the Healthcare Business Women’s Association. She was named one of Fierce Biotech’s "Women in Biotech" and a "Women Who Mean Business" from the Washington Business Journal. In 2013, Dr Jallal earned the Grace Award from Cancer Research Institute. Prior to joining MedImmune, Dr Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Saugeen, Inc. where she held positions of increasing responsibility leading to Senior Director, Research. Dr Jallal received a Master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
As Chief Executive Officer of Axovant, David Hung has a background that spans basic scientific research, clinical experience, entrepreneurial and business expertise, and creative passions. Previously, he was a Co-Founder, President and Chief Executive Officer of Medivation, Inc., until its acquisition by Pfizer Inc. in 2016 for $14.3bn. At Medivation, Dr Hung identified, in-licensed and led bench-to- bedside development of XTANDI, which is now the leading drug in the world for the treatment of advanced prostate cancer and qualifies for blockbuster status, having exceeded $2.2bn in global annual sales in 2016. Prior to that, Dr Hung served as Chief Scientific Officer and then as President and Chief Executive Officer at ProDuct Health, Inc. (which developed a minimally invasive microcatheter to procure cells from the breast milk ducts for the early detection of breast cancer and breast cancer risk assessment) until the acquisition of ProDuct Health, Inc. by Cytyc Corporation in 2001 for $168m.
Dr Hung received his A.B. in Biology and Organic Chemistry from Harvard College, and his MD from the University of California, San Francisco (UCSF) School of Medicine. He also completed clinical training in internal medicine, hematology, oncology, and transfusion medicine and then two basic science postdoctoral fellowships in brain tumor and cardiovascular research, all at UCSF School of Medicine.
Richard Mason is the Head of Johnson & Johnson London Innovation Centre and is responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr Mason leads a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early stage partnerships and investments across all three sectors of Johnson & Johnson. Prior to joining Johnson & Johnson Innovation, he was CEO of XO1 Limited until the company was acquired by Janssen in March 2015. Prior to his role at XO1, Dr Mason was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions. Mr Mason also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT). Dr Mason trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree Immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals
Nicola Bedlington joined the European Patients’ Forum as its first Executive Director in June 2006. In this capacity, she is the Co-ordinator of the European Patient Academy on Therapeutic Innovation (EUPATI). From 2004 to 2006, she worked for the Swiss Government, leading the Environment and Schools Initiatives Secretariat (ENSI), an international government-based network set up by OECD focussing on innovation, action research and policy development in the field of Education for Sustainable Development. Whilst in Switzerland, she has also worked as an independent consultant/evaluator, specialising in European social and development policy and health advocacy. Ms Bedlington was the founding Director of the European Disability Forum, an umbrella organisation uniting over 70 European disability NGOs and National Councils of Disabled People to advocate for the human rights and inclusion of disabled citizens in Europe (1996 to 1999), and prior to this she worked as an external expert for the European Commission, heading the NGO unit within the HELIOS Programme, a European Commission Action Programme promoting equal opportunities for disabled people (1991-1996). Ms Bedlington studied Business and Human Resource Management in the UK and France.
José Luis Molinuevo
José Luis Molinuevo is the Scientific Director of the BarcelonaBeta Brain Research Centre of the Pasqual Maragall Foundation. His clinical work and research activities relate primarily to Alzheimer’s disease and associated disorders and he is currently focus in studying the preclinical stage of the disease and the development of prevention strategies. In addition to this role, he is also a researcher at the Institut D’Investigacions Biomèdiques August Pi I Sanyer (IDIBAPS), a member of the European Alzheimer Disease Consortium and the dementia panel for the European Association of Neurology, as well as the Alzheimer Biomarker Standardisation Initiative. Additionally, he is Spanish coordinator of the Biomarkers for Alzheimer’s and Parkinson’s Disease (BIOMARKAPD) group of the Joint Programming on Neurodegenerative Diseases, and Partner and Co-Lead of several Innovative Medicine Initiative consortiums, such as AETIONOMY, EPAD, AMYPAD. He also works with the International Working Group (IWG) and NIA-AA for developing new research criteria, and is a member of the AUC for CSF analysis working group. He has published over 220 international scientific papers, several books and over 20 book chapters on neurodegenerative diseases. He served on the board of directors of the Spanish Neurological Society from 2000 to 2002 and coordinated the dementia scientific group from 2006 to 2008. He was awarded with the ICGP international junior investigator award in 2003 and the AD scientific prize of the Spanish Neurological Society in 2010. His served as a physician at the University of Valencia, having received his neurology training at the Hospital Clinic de Barcelona. His PhD on Parkinson’s disease was completed at the University of Barcelona.
Sarah Haywood became Chief Executive Officer of MedCity in December 2015, having previously served as Interim CEO, and prior to that as Chief Operating Officer since MedCity’s launch in April 2014. She joined from London & Partners where she worked with Dr Eliot Forster to establish MedCity as a leading hub for life sciences research, development and commercialisation. Ms Heywood is a graduate of the NHS Management Training Scheme in Wales ,and worked in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit located on the University ColleageLondon (UCL) campus. From there, Ms Heywood undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BEIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BEIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. Ms Heywood has a degree in Biology from the University of Oxford, a post graduate diploma in Management and an MA in Human Resources Management; she is a Chartered Fellow of the Chartered Management Institute.
David Hodgson is the global lead of Deloitte’s Life Sciences Risk Advisory practice. He has over 20 years of life sciences consulting and advisory experience across multiple private and public sector clients. Mr Hodgson leads a number of Deloitte’s key risk, regulatory and commercial compliance programmes for Life Sciences clients and has worked extensively at board level across all areas of the regulatory and compliance agenda.
Sir Andrew Dillon
Andrew Dillon is Founder and Chief Executive of the National Institute for Health and Care Excellence (NICE), a position he has held since 1999. Prior to this, he held a number of senior management positions in the UK National Health Service, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust, both academic medical centres in London. He graduated from the University of Manchester in 1975.
Professor Guido Rasi was appointed as Principal Adviser in Charge of Strategy of the European Medicines Agency in 2014. Prior to this, from 2011 to 2014 he was the Executive Director, and from 2008 to 2011 a Member of its Management Board of the Agency. He also held the post of Director-General of the Italian Medicines Agency from 2008 to 2011, and was a member of the Agency’s Management Board from 2004 and 2008. This followed a prior career in academia. Professor Rasi was appointed Professor of Microbiology at the University of Rome 'Tor Vergata' in 2008. From 2005 to 2008 he was Director of the Institute of Molecular Medicine of the National Research Council in Rome and from 1990 to 2005, he worked at the Institute for Experimental Medicine of the National Research Council, Italy. He also had teaching and research experience at the University of California, Berkeley in 1999. Professor Rasi holds a degree in Medicine and Surgery, with specialisations in Internal Medicine, Allergology and Clinical Immunology from the University of Rome. From 1978 to 1990, he worked as a physician in hospital based, research and private practice. He is author of more than 100 scientific publications.
Rod MacKenzie is Executive Vice President, Chief Development Officer for Pfizer. In this role, he is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including cardiovascular and metabolic disease, inflammation and immunology, neuroscience, oncology and rare disease. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximising the return on R&D investment across the Pfizer portfolio, and is a member of Pfizer’s Executive Leadership Team.
Dr MacKenzie joined Pfizer in Sandwich, UK as a Research Scientist. He is the co-inventor of darifenacin (Enablex™). Dr MacKenzie has held numerous leadership positions at Pfizer, including Head of PharmaTherapeutics Research and Development. He also served as Site Director of the Groton, Connecticut laboratories, Pfizer’s largest global R&D facility. Prior to this role, Dr MacKenzie held a series of research leadership positions, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, UK, Head of the Discovery Technology Center in Cambridge, Massachusetts, Head of Discovery Research in Ann Arbor, Michigan, and Head of Drug Safety R&D.
Dr MacKenzie represents Pfizer on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV.Dr MacKenzie graduated from the University of Glasgow with a 1st Class Honours degree in chemistry and completed his PhD at Imperial College, London.
Stephen Moran is Global Head of Strategy for Novartis, a position he has held since January 1, 2017. Dr Moran joined Novartis in January 2015 as Strategic Assistant to the CEO. Prior to that, he was an Associate Principal at McKinsey & Company, serving as a leader in the healthcare practice. There his work focused on health system sustainability, research and development strategy and the economic analysis of clinical interventions across disease pathways. Dr Moran holds a Bachelor of Arts and a Master of Science in Natural Sciences from the University of Cambridge in the United Kingdom, and a doctorate in Biochemistry from the University of Oxford.
Andrew Hopkins is the Founder and CEO of Exscientia Ltd. Exscientia is an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery. Mr Hopkins is the author of some of the most highly cited papers in modern drug discovery. He spent ten years at the Pfizer, following his DPhil at the University of Oxford. Subsequently, he was one of the youngest professors when he was appointed to a Chair at the University of Dundee. Mr Hopkins has raised around £50m for commercial and academic research activities. He has won several awards for his work including the Royal Society of Chemistry’s Entrepreneur of the Year and the Capps Green Zomaya Medal, the BBSRC Commercial Innovator of the Year, Scottish Enterprise Life Science Entrepreneurial Leadership Award, and the Corwin Hansch Award. Mr Hopkins is a Fellow of the Royal Society of Edinburgh (RSE) , the Royal Society of Chemistry (RSC), the Royal Society of Biology (RSB) and the Learned Society of Wales (LSW) .
Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations. Before starting DayTwo, she was COO and CFO of Sisense, a provider of business intelligence and analytics software. For more than fifteen years prior to that she has held senior roles in a number of businesses, from start-ups to large public enterprises. She is a certified Lawyer, with an LLB from the Tel-Aviv University, and has an MBA from Northwestern University, USA.
Andrew Thompson is Co-Founder, President and Chief Executive Officer of Proteus Digital Health. His vision for digital medicines is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone's pocket. He is also a Co-Founder and Board Member of Summit Schools, a leading Charter High School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie Waiting for Superman.
Mr Thompson is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies. He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.
Deborah Waterhouse became Chief Executive Officer of ViiV Healthcare in April 2017. She brings a wealth of experience to ViiV Healthcare having lived and worked in Europe, Asia and the USA, and has a strong track record of performance in both specialty and primary care. She joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business. She also led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.
Kevin Pojasek is Vice President, Director of Corporate Strategy and a member of the executive leadership team at Immunocore. He is responsible for shaping the company’s corporate, R&D and growth strategies alongside members of the senior team and the board of directors. In addition, he is co-head of the company’s Infectious Disease Unit. Prior to joining Immunocore in 2016, Dr Pojasek was President and Chief Executive Officer of Quartet Medicine, a Cambridge, MA-based start-up discovering and developing novel treatments for chronic pain and inflammation. Under Dr Pojasek’s leadership, Quartet raised over $23m in Series A financing and entered into a strategic research partnership and option-to-acquire agreement with Merck for up to $595m. Dr Pojasek co-founded Quartet in late 2013 as an entrepreneur-in-residence at Atlas Venture. While working with Atlas, Dr Pojasek was also the Chief Operating Officer of Annovation Biopharma, a clinical-stage company developing novel intravenous anesthetics, which was sold to the Medicines Company in 2015. Dr Pojasek has also held senior executive R&D and corporate development roles at several venture capital-backed companies and, earlier in his career, spent time as an investment associate at PureTech Health (LSE: PRTC) an early stage venture capital. Dr Pojasek received his PhD from the Biological Engineering Department at Massachusetts Institute of Technology and his BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.
Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Under Mr Firth’s leadership, ASLAN has become Singapore’s first publicly listed biotech, completing an initial public offering in June 2017 with a listing on the Taipei Exchange. Previously, Mr Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, he worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Mr Firth was chosen as one of SCRIP’s top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of Merck, and Andrew Witty, CEO of GlaxoSmithKline. Mr Firth holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University .He is a member of Singapore’s Health and Biomedical Sciences International Advisory Council. He is also an Independent Director of Hong Kong listed Uni-Bio Sciences and Singapore’s Exploit Technologies, and is an Adjunct Professor at DukeNUS Medical School.
Francesco De Rubertis
Vada Perkins is Managing Principal of IDENTIFICA, an independent global regulatory intelligence and life sciences IT practice with a wealth of knowledge and experience in regulatory science, international data standards, and Global Product Lifecycle Data Management (G-PLDM™).
Mr Perkins has extensive experience in the development, interpretation, and implementation of guidance, regulations, and international standards to support the comprehensive review of drugs, biologics, and devices throughout the product lifecycle. His expertise in regulatory science supports proactive collaboration with national and international stakeholders to harmonize regulatory activities in the development of innovative approaches to better assess the safety, efficacy, quality, and performance of medicinal products worldwide. Mr Perkins formally represented the US. and FDA as a Senior Advisor for Regulatory Science and Acting Deputy Associate Director for Review Management and worked in concert with leadership and staff on a broad range of regulatory and policy issues. He has comprehensive knowledge of product labelling and drug supply chain initiatives related to product/establishment identification, lot distribution, serialisation, falsified medicines, combination products, and unique device identification. He has received numerous awards which includes the FDA Commissioner’s Special Citation. Mr Perkins received his degrees from Johns Hopkins University, University of Southern California, and the University of Maryland-Baltimore.
Dmitry Kaminskiy is is an innovative entrepreneur and investor who is a Co-Founder and a Senior Partner at Deep Knowledge Ventures, a Hong Kong based investment fund focused on disruptive DeepTech, AI, BlockChain, Cryptoeconomy, and the synergetic convergence of ultra-innovative technologies. In view of the significant growth of interest to the longevity industry, Deep Knowledge Life Sciences, a London-based subsidiary investment fund has increased its investment activity in 2017 and will actively expand its portfolio to catch the wave edge of the rising trend “Investing in Longevity”. In addition to his business experience, Mr Kaminskiy is involved in several scientific endeavours. He strongly believes that humans should live longer healthier lives. He has a major interest is anti-aging and healthy longevity which is reflected in his business, research and public activities. Mr Kaminskiy is well known for his support of life extension think-tanks in Oxford and Cambridge and many other non-profit activities. Mr Kaminskiy’s US$1 million prize for the first person to reach their 123th birthday went viral, and was widely covered by the world’s top media.
Ori Hershkovitz co-founded NEXTHERA Capital, a healthcare dedicated hedge fund, in 2015 and acts as its Chief Investment Officer. Mr Hershkovitz has 19 years of experience covering and investing in the healthcare sector. From 2006 to 2014, he was a founding member of the Sphera Global Healthcare Fund where he served as Head of Research. Prior to joining Sphera, he held several senior pharmaceutical equity analyst roles at Leader & Co (from 2001-2006) and at Ilanot Batucha Investment House (from 1998-2001). In the course of 2014, Mr Herhkovitz was the head lecturer for a healthcare analyst course sponsored by the Tel Aviv Stock Exchange, which was attended by leading investors and healthcare executives from across the globe. He earned a Bachelor's degree in Business Administration and Finance from Tel Aviv University.
Chairs and Moderators (3)
David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.
Mr Crow has an MA in English Literature from the University of Glasgow.
Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.
Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.
Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.
Agenda - 9th Nov
9:00amOpening remarks from the Chair
Sarah Neville, Global Pharmaceutical Editor, Financial Times
Simon Stevens, Chief Executive Officer, NHS England
9:25am‘Way to Play’: Embracing Strategic Opportunities in the New Health Economy
The recent history of pharma has been one of significant value destruction. Returns for shareholders look set to become in increasingly commensurate with those from commoditised industries – a position forecast only to intensify as pricing and other industry pressures start of bite. New ways to create value will need to be found if the industry is to continue to win favour with investors and strategies will need to be defined which will enable them to compete, to adapt and to embrace many of the new opportunities emerging in the new health economy. From high science, high premium and digitally enhanced business models to strategies based on developing off-the-shelf IP acquired from big pharma, what are the ‘ways to play’ to create value and growth in life sciences? What are the risk and opportunities in the various approaches?
Session Keynote: Belén Garijo, Member of the Board and CEO, Healthcare, The Merck Group
Kemal Malik, Member of the Management Board, Bayer
Jeremy Levin, Chairman and CEO, Ovid Therapeutics
Ameet Nathwani Executive Vice President, Group Chief Medical Officer, Sanofi
Christian Mazzi, Chief Commercial Officer and Managing Director Established Brands, Mundipharma
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
10:10amGetting the Big Picture: Geopolitical and Economic Risk-What Lies Ahead?
From the backlash against globalisation and its impact on trade and globally integrated supply chains to the decline in economic growth and structural challenges in emerging markets-what is the industry vulnerability to geopolitical risk, and the macroeconomic exposure it faces? What are the external forces currently at play which will add considerably to the industry’s exposure to risk? What lies ahead for US healthcare reform in the months and years ahead, and how are healthcare and life science companies addressing this uncertainty? What is the impact of Brexit and other potential disruptive political events in Europe for the life sciences industry -for instance, the impact for research, immigration, trade, IP, harmonisation of regulations, and HTA?
David Meek, CEO, Ipsen
Beijia Ma, Equity Strategist, Bank of America Merrill Lynch
Kevin Pojasek, Vice President, Director of Corporate Strategy, Immunocore
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
10:50amNetworking Coffee Break
11:05amFT CEO Keynote Interview
Vivek Ramaswamy, Chief Executive Officer, Roivant Sciences in conversation with David Crow, Senior US Business Correspondent, Financial Times
11:20amPanel: Adopting Open Innovation-Location, Strategies, Risks
Open innovation continues as a core strategy for life science companies in their drive to increase the productivity of their R&D. Location is key to the success of such efforts. For years, big pharma has been situated in fortress-like corporate campuses in places like New Jersey, Indiana and the Chicago suburbs. But increasingly, drugmakers are moving scientists to biotech clusters in coastal America and in Cambridge, UK. Here they can be close to the world's leading academic centres and younger drugmakers, guaranteeing access to early-stage science. What makes these "clusters" tick and what are the new hot areas to watch? Are clusters the best way to achieve enhanced collaboration? What are the opportunities, challenges and risks (e.g. IP) of open innovation? What are the lessons from early adapters and the outcomes?
Patrick Vallance, President, R&D, GlaxoSmithKline
Gabriel Baertschi, Chairman and CEO, Grünenthal
Sarah Haywood, Chief Executive Officer, MedCity
Tauhid Ali, Vice President, Head of TAK-celerator, Centre for External Innovation (CEI), Takeda International
Alexandra Eberhard, Managing Director, EMEA, Signals Analytics
Moderator: David Crow, Senior US Business Correspondent, Financial Times
12:00pmRight Sizing Regulation
As the debate regarding regulation moves centre stage with calls increasing for a loosening of regulation, speakers will discuss the pros and cons of less onerous regulation and drug approval. Are we seeing a politicisation of the debate of the drug approval process, with standards compromised and regulators ceding to patient pressures? As research breakthroughs continue to advance the boundaries of what’s possible in treatments, can we expect more coordinated campaigns as desperate patients strive to bend the regulatory rules rule in their favour? Or does regulation require a fundamental rethink? Should the focus be on safety, with efficacy left to doctors and patients?
David Hodgson, Global Life Sciences & Health Care Risk Advisory Leader, Deloitte
Vada Perkins, Founder and Managing Principal, IDENTIFICA Global Regulatory Consultancy
Nicola Bedlington, Secretary General, European Patients’ Forum
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
1:50pmPricing and Access
Concerns regarding pricing and access remain central to the industry’s future profitability and sustainability. What are the emerging developments with regards to pricing, and potential solutions to the current impasse? Will self-regulation be sufficient? Will regulators, payers and patients continue to reward innovation?
Michael Nally, President, Global Vaccines, Merck & Co
Sir Andrew Dillon, Chief Executive Officer, NICE
Sarah Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER)
Deborah Waterhouse, CEO, ViiV Healthcare
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
2:30pmRealising the Potential of Real World Evidence (RWE)
As pharma companies continue to grapple with RWE, we hear from leaders in this field, who have developed end-to-end RWE capabilities, with insights into emerging best practice, and views on the remaining challenges in realising the full potential of RWE.
Andy Schmeltz, Senior Vice President, Patient & Health Impact, Pfizer
David Leather, Medical Vice President for Respiratory Franchise, GlaxoSmithKline
Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
3:05pmNetworking Coffee Break
3:20pmTransforming Clinical Trials to move them to a 21st Century Paradigm
Rod MacKenzie, Executive Vice President, Chief Development Officer, Pfizer in conversation with Sarah Neville, Global Pharmaceutical Editor, Financial Times
3:40pmPanel: Focus on Cancer
Given recent high profile knockbacks in trial results, what is the outlook for the burgeoning immuno-oncology space? Will the hopes for solutions in cancer combination therapies be realised? What are the prospects and challenges for emerging cancer therapies, to include CAR-T? As the level of competition in cancer therapies increases, will the field become increasingly commoditised? How could a growing focus on prevention, rather than cure impact financing and research on cancer?
André Choulika, Chairman and Chief Executive Officer, Cellectis
Christian Hogg, Executive Director and Chief Executive Officer, Chi-Med
David Berman, Senior Vice President, Immuno-Oncology Franchise Head, MedImmune/AstraZeneca
Moderator: David Crow, Senior US Business Correspondent, Financial Times
4:20pmThe Trouble with Alzheimer’s: Transforming Treatment, Prevention and Care
Dementia-an ‘unstoppable epidemic, with Alzheimer’s at its core-is a leading cause of mortality in both the developed and developing world, and the enticing economics of ageing populations is drawing growing numbers of in pharmaceutical and healthcare companaies into finding solutions the improve the treatment prevention and care of the disease. Yet progress has been slow, with no new treatments in a decade and recent drugs hailed to have promise failing in clinical trials. With the amyloid plaque theory now in doubt, is it time to evaluate alternative approaches, and which central theory is likely to guide further research efforts? Should the focus of research and investment now move to prevention? What are the innovations in diagnostics and technologies (e.g. robotics. AI, IoT, telecare etc.). prevention and care which could revolutionise the field?
Session Keynote: David Hung, Chief Executive Officer, Axovant
Amit Roy, Founding Partner, Foveal
Henry Mahncke, Chief Scientific Officer, Posit Science
José Luis Molinuevo, Scientific Director, Barcelona Beta Brain Research Centre, Pasqual Maragall Foundation
Nuala Murphy, President, Clinical Research Services, Icon
Samantha Budd Haeberlein, Vice President, Alzheimer’s Clinical Development, Biogen
Moderator: David Crow, Senior US Business Correspondent, Financial Times
5:00pmInvestor Panel: How do the Markets View the Future for the Industry?
In this final session of the day, our panel of leading investment bankers, venture capitalists and private equity specialists, and industry analysts share their views on how they see the sector changing and the potential headwinds and opportunities ahead.
Ori Hershkovitz, Founder and Chief Innovation Officer, NEXTHERA Capital
Francesco De Rubertis, Co-Founder, Medicxi
Knut Slatten,Vice President – Senior Analyst , Corporate Finance Group, Moody's
Lisa Urquhart, Editor, EP Vantage
Moderator: David Crow, Senior US Business Correspondent, Financial Times
5:40pmClosing remarks from the Chair
Agenda - 10th Nov
9:00amOpening remarks from the Chair
Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
Flemming Ornskov, Chief Executive Officer, Shire in conversation with Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
9:25amPanel: Strategy Forum
In this session, our panel of strategists from leading pharma companies share their views on the megatrends ahead with the potential to further transform the industry.
Stephen Moran, Global Head of Strategy, Novartis
Richard Mason, Head of Johnson & Johnson Innovation, EMEA
Carl Firth, Founder and CEO, Aslan Pharmaceuticals
Emmanuel Ligner , President and CEO , GE Healthcare Life Sciences
Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte Touche Tohmatsu
10:05amFT Keynote Interview
Steve Cutler, CEO, Icon
10:25amPanel: How Will Precision Medicine Transform Healthcare and Life Sciences?
Precision medicine-the tailoring of medicine and healthcare to a person’s individual’s genes, lifestyle and environment- is making steady inroads, but how can the full potential of precision medicine be better harnessed, and its economic model and utility enhanced? With the more accurate diagnostics and the more precise disease classification precision medicine enables, what are the implications for drug research and for healthcare systems currently built around disease specific specialisations? As geneticists and computational experts take on a greater role, what will be the role for the physician? With more tailored and individualised treatments, will life science companies successfully embrace opportunities emerging along the’ patient journey’? With the transition to value-based care models expedite the uptake of precision medicine?
Herve Hoppenot, President and Chief Executive Officer, Incyte Corp
Bahija Jallal, Executive Vice President, AstraZeneca and Head, MedImmune
Régis Senegou, Co-Founder and CEO, Sivan Innovation
Othman Laraki, CEO, Color Genomics
Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
11:05amFood as Medicine
As an understanding of the link between food and health and the role of the microbiome grows, food companies are moving into the field of therapeutic and personalised nutrition, and behaving increasing like drug companies through a focus on regulated products. What are the implications for life science companies? To what extent are these developments a threat or an opportunity to pharma? What are the prospects for personalised nutrition products based on gene/ biome type? Will food become a normal part of prescribing alongside pharmaceutical products?
Lihl Segal, Co-Founder and CEO, DayTwo
Jason Langheier, CEO & Founder, Zipongo
Rolf Smeets, Chief Medical Officer, Nutrica Advanced Medical Nutrition
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
11:35amNetworking Coffee Break
11:50amSocial Prescribing - The Next Big Thing?
With social prescribing playing an ever greater role in the medical professional’s toolbox, what are the implications for pharma? What is the evidence of the impact of social prescribing on health outcomes? Should health services pay? Will traditional drug based therapies and adherance be compromised, with detrimental impacts on health?
Stacy Lindau,Founder and Chief Innovation Officer, NowPow
12:10pmAging and Longevity
A growing number of healthcare companies and investment capital is making its way into the study of aging with the aim not only of extending healthspan -but also of studying the link between the processes of aging with a view to halting the onset of and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which aging could be viewed as just another disease to be ‘cured’, resulting in a less crippling and costly burden from age-related drug development and for care within the healthcare system. How far along are we in better understanding aging, and when might we see the testing and potential approval of anti-aging drugs in humans? What are the practical and philosophical challenges which need to be addressed before the development of anti-aging drugs arrives in earnest?
Dmitry Kaminsky, Co-Founder and Senior Partner, Deep Knowledge Ventures
Alex Zhavoronkov, CEO, In Silico Medicine,Inc
Joseph Antoun, President & CEO, L-Nutra
Michael West, Co-CEO, AgeX Therapeutics
Moderator: David Crow, Senior US Business Correspondent, Financial Times
12:50pmDisrupt or Be Disrupted: The Big Digital Debate
Will pharma companies flourish or flounder in the new digitised healthcare world which is emerging? While pharma companies are recognising the value of digital products and services, their initiatives to date can appear as isolated beacons in a sea of change sweeping the healthcare industry. Will the industry be upended by data and consumer savvy new entrants who are impinging even into the core R&D business of pharma? Or will the industry traditional strengths in R&D, IP, risk management and complexity set them apart from the competition? Can they own and successfully navigate ‘the last mile’ to the customers ensure their place as winners in the hew health economy which is emerging?
Karennan Terrell, Chief Digital and Technology Officer, GSK
Adam Hill, Chief Medical Officer, McLaren Applied Technologies
Andrew Hopkins, Chief Executive Officer, Exscientia
Élie Lobel ,CEO, Healthcare, Orange
Ulrich Muehlner, Chief Executive Officer, GrowthCube Partners
Moderator: Greg Reh, Global Life Sciences and Health Care Industry Leader, Deloitte
1:35pmClosing Remarks from the Chair
1:40pmClose of Conference
- Review the diverse strategies life science companies are adopting to position themselves for growth and to navigate the emerging value and outcomes terrain
- Debate the potential to greater cross-industry and cross-sector collaboration in the race for faster, cheaper, better cures
- Hear from those who are turning the vision of personalised medicine into a clinical reality for patients today, and their views on the challenges ahead
- Deep dive on the trouble with Alzheimer's and review the solutions to transforming treatment, prevention and care.
- Learn the latest on food as medicine - what is the opportunity and the challenge for pharma?
- Join the debate on how to right size regulation as the push for faster drug approval and less onerous regulation gains momentum
- Disrupt or be disrupted: as digital gains steam, will pharma flourish or flounder?
- Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Global Pharmaceutical and Biotechnology Conference will be attended by:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic and medical devices
- Healthcare providers and insurers
- Government healthcare departments, HTA’s and drug regulators
- Digital health companies
- Genomics and personalised medicine experts
- IT, big data and analytics providers
- Health economists
- Healthcare investment bankers, private equity and venture capitalists
- Healthcare lawyers and management consultants
- Patient representatives and NGOs
Presented By (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. Providing essential news, comment, data and analysis for the global business community, the FT has a combined paid print and digital circulation of 840,000. Mobile is an increasingly important channel for the FT, driving more than half of total traffic.
With the Support Of (1)
About Life Sciences and Health Care at Deloitte*
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Lead Sponsor (2)
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and to government. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON has built a reputation as an industry innovator and expert in transforming pharma R&D through strategic partnerships and alliances. The company’s expertise in managing and interpreting large clinical and real-world data sets has led to its selection by organisations involved in key transformative projects, including the 100,000 Genomes Project, the world’s largest genome sequencing project for cancer and rare diseases. ICON has also been chosen by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the creation of the world’s first global healthcare outcomes benchmarking program.
With headquarters in Dublin, Ireland, ICON currently operates from 88 locations in 37 countries and has approximately 12,600 employees. For further information please visit www.iconplc.com. Follow @iconplc on Twitter.
Signals Analytics' journey began in 2009 when two Israeli military intelligence officers with decades of combined experience in utilizing open source (OSINT), signals (SIGINT) and human (HUMINT) intelligence to enable covert operations realized that the same concepts, processes and technologies deployed in the battlefield could be utilized to make better decisions in the boardroom.
Eight years later and we are a 150-person strong augmented intelligence company headquartered and growing in New York with offices in Geneva and Tel Aviv. We've created system of insight that transforms the world’s unconnected data into actions to optimize product portfolio health, accelerate new product development and propel breakthrough innovations. And we are honored to enable over 60 of the world’s top brands to continuously experience the “aha moment”.
Associate Sponsors (3)
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data, insights, combined with personalised, expert client support.
Our online subscription services cover the pharmaceutical, biotech and medtech sectors.
EP Vantage our independent, award-winning editorial team offers data-driven, forward-looking news, commentary and analysis on a daily basis.
EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.
EvaluateMedTech® sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.
EvaluateClinical Trials® delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.
Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.
The Evaluate services enable the life science community to make sound business decisions about value and opportunity.
Mundipharma’s history began when the first entity was established in Switzerland in 1957 – the first of many. Since then Mundipharma has created a strong legacy, dedicated to alleviating human suffering and improving quality of life for patients. Our patient-centric approach is supported by innovation, enabling scientific breakthroughs that result in better medicines. In addition, our entrepreneurial spirit has enabled us to grow, and in doing so, increase the number of patients we can reach. With our regional emerging markets hub in Singapore, offices in countries across Asia Pacific, Latin America, the Middle East and Africa, and a global network, our medicines now touch the lives of patients in six continents.
Mundipharma is focussed on creating new, transformative ways to help doctors and patients, and developing innovative new medicines to meet future healthcare challenges. We are also working to improve patient access to essential medication, and doctor education, in underdeveloped areas. Mundipharma will always be focused on improving patients’ quality of life.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. www.pfizer.com
Supporting Partners (5)
European Pharmaceutical Review is the leading bi-monthly publication for information on technologies in drug discovery and manufacturing. Every issue offers a high level of technical and business contributions from the world's leading pharmaceutical companies and academic institutions, coupled with new and exciting features including interviews, updates and profiles.
Established in 1986, the Pharmafocus brand continues to be the most read and respected news portal in the pharmaceutical and biotech industry, with a team of dedicated journalists constantly updating the website; pharmafile.com, monthly newspaper Pharmafocus and daily e-newsletters with the latest quality global news, thoroughly researched analysis, market intelligence and high profile interviews. Covering important issues affecting the industry from the early stages of drug development, clinical trials, manufacturing, market access and global logistics.
PharmaBoardroom.com’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.
Download our latest country report on
Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 45,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
222 Marylebone Road
London NW1 6JQ
United KingdomTel: +44 (0) 20 7631 8000